[Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL] - PubMed
Review
. 1996 Oct;23(12):1679-80.
[Article in Japanese]
Affiliations
- PMID: 8886044
Review
[Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL]
[Article in Japanese]
Y Masaki et al. Gan To Kagaku Ryoho. 1996 Oct.
Abstract
A new therapeutic strategy for pancreatic cancer is needed because of its very poor prognosis. We presented the results of adoptive immunotherapy and new adoptive immunotherapy using MUC1 specific CTL. We expect that these new strategies may help improve the prognosis of pancreatic cancer.
Similar articles
-
Kondo H, Hazama S, Kawaoka T, Yoshino S, Yoshida S, Tokuno K, Takashima M, Ueno T, Hinoda Y, Oka M. Kondo H, et al. Anticancer Res. 2008 Jan-Feb;28(1B):379-87. Anticancer Res. 2008. PMID: 18383873 Clinical Trial.
-
[Strategy of treatment for pancreatic and biliary cancer with special reference to immunotherapy].
Oka M, Suzuki T. Oka M, et al. Gan To Kagaku Ryoho. 1994 Aug;21(10):1571-6. Gan To Kagaku Ryoho. 1994. PMID: 8060130 Japanese.
-
Kawaoka T, Oka M, Takashima M, Ueno T, Yamamoto K, Yahara N, Yoshino S, Hazama S. Kawaoka T, et al. Oncol Rep. 2008 Jul;20(1):155-63. Oncol Rep. 2008. PMID: 18575732
-
[Adoptive immunotherapy using MUC1--specific CTLs for unresectable pancreatic cancer].
Kawaoka T, Takashima M, Yamamoto K, Ueno T, Oka M. Kawaoka T, et al. Nihon Rinsho. 2006 Jan;64 Suppl 1:279-82. Nihon Rinsho. 2006. PMID: 16457266 Review. Japanese. No abstract available.
-
MUC1 as a target antigen for cancer immunotherapy.
Acres B, Limacher JM. Acres B, et al. Expert Rev Vaccines. 2005 Aug;4(4):493-502. doi: 10.1586/14760584.4.4.493. Expert Rev Vaccines. 2005. PMID: 16117706 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous